figshare
Browse

Julie Decock

0000-0002-4409-100X

Post-doc (Oncology and carcinogenesis not elsewhere classified)

Doha

I was born in Brugge on July 11th 1980 and lived for 6 years of my childhood with my parents and sister Sofie in Kaliemi, Zaïre. From 1992 to 1998 I went to secondary school (Latin-Mathematics) at the ‘Sint Andreas Lyceum’ in Sint-Kruis. After this I attended the Free University of Brussels, where I graduated Master in Biomedical Sciences in 2002. For my master thesis I investigated, under the supervision and guidance of Prof. J. De Grève and dr. E. Teugels, whether heterozygote BRCA1 and BRCA2 mutations result in an increased genomic instability. This is where my interest for cancer research sparked. In 2003, I started my PhD in Medical Sciences at the Leuven Cancer Institute under the supervision of Prof. R. Paridaens and Prof. A. van Oosterom. I examined the clinical relevance of proteases, in particular matrix metalloproteinases and cathepsins, in breast cancer. I had the opportunity to join the European Cancerdegradome project and was able to forge various collaborations resulting in a number of publications. After my PhD I joined the research group of Prof. D.R. Edwards from the University of East Anglia in the UK and have been part of his team since then. I have expanded my knowledge of the degradome in a range of cancer types, including breast cancer, prostate cancer and more recently pancreatic cancer as part of the European SaveMe project. I have strengthened my expertise in cancer biology using both in vitro and in vivo models. Besides my research activities I am also involved in charity work through the local Big C charity, and university policies on various levels such as the School's health and safety committee and Athena Swan Focus group.

Publications

  • TGF-β-Elicited Induction of Tissue Inhibitor of Metalloproteinases (TIMP)-3 Expression in Fibroblasts Involves Complex Interplay between Smad3, p38α, and ERK1/2 DOI: 10.1371/journal.pone.0057474
  • Matrix metalloproteinases: Protective roles in cancer DOI: 10.1111/j.1582-4934.2011.01302.x
  • The roles of ADAMTS metalloproteinases in tumorigenesis and metastasis DOI: 10.2741/3827
  • Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: Triple positive tumours are more likely lymph node positive DOI: 10.1007/s10549-008-9914-7
  • Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors DOI: 10.1007/s10549-008-0110-6
  • Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer DOI: 10.1007/s10549-007-9687-4
  • Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer
  • Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer DOI: 10.1111/j.1399-0004.2007.00946.x
  • Plasma MMP1 and MMP8 expression in breast cancer: Protective role of MMP8 against lymph node metastasis DOI: 10.1186/1471-2407-8-77
  • Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis DOI: 10.1158/0008-5472.CAN-07-1683
  • Loss of nuclear BRCA1 protein staining in normal tissue cells derived from BRCA1 and BRCA2 mutation carriers DOI: 10.1016/j.mrfmmm.2007.02.031
  • Matrix metalloproteinase expression patterns in luminal A type breast carcinomas
  • How accurate is the antiprimer quenching-based real-time PCR for detection of Her2/neu in clinical cancer samples? [8] DOI: 10.1373/clinchem.2006.069427
  • Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables DOI: 10.1007/s10585-005-3992-2
  • Proteases and metastasis: Clinical relevance nowadays? DOI: 10.1097/01.cco.0000180435.39614.63
  • Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive DOI: 10.1007/s10549-008-9914-7
  • Loss of nuclear BRCA1 protein staining in normal tissue cells derived from BRCA1 and BRCA2 mutation carriers DOI: 10.1016/j.mrfmmm.2007.02.031

Usage metrics

Co-workers & collaborators

Wouter Hendrickx

Investigator - Doha - Qatar

Wouter Hendrickx

Jessica Roelands

Post-doctoral researcher - The Netherlands

Jessica Roelands

Julie Decock's public data